SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) October 31, 1997
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On October 31, 1997, Biocontrol Technology, Inc. (NASDAQ:BICO) announced today
that in mid-November its subsidiary, Diasense, Inc., will commence shipping its
Diasensor 1000 noninvasive glucose sensors for sale in Manila, Philippines.
Along with the sensors, Biocontrol expects to send to Manila a medical team to
facilitate the startup. Biocontrol further announced that a meeting with the
Food and Drug Administration (FDA) was held earlier this week. Helpful
additional insight was gained and will be incorporated into the Company's
submission which the Company continues to work on and will submit as soon as
possible.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by
the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper, CEO
DATED: October 31, 1997
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.279.9455 phone
1.412.279.9690 fax 1.412.279.9447 fax
BIOCONTROL TO BEGIN SALES OF THE DIASENSOR 1000
Pittsburgh, PA, October 31, 1997 - Biocontrol Technology, Inc.
(Nasdaq:BICO) announced today that in mid-November its subsidiary,
Diasense, Inc., will commence shipping its Diasensor 1000 noninvasive
glucose sensors for sale in Manila, Philippines. An agreement with an
established Philippine company that will act as distributor and service
agent is being finalized. Along with the sensors, Biocontrol expects to
send to Manila a medical team to facilitate the startup. Manila has
been targeted at this time because of strong interest in, and
commitment to, sales of the Diasensor 1000 in a market of 13 million
people. Biocontrol is also currently investigating the possibility of
setting up a manufacturing facility in the Philippines to reduce
production and distribution costs to that part of the world. Biocontrol
further announced that a meeting with the Food and Drug Administration
(FDA) was held earlier this week. Helpful additional insight was
gained and will be incorporated into the Company's submission which the
Company continues to work on and will submit as soon as possible.
Without the need to finger prick, the Diasensor 1000 measures blood
glucose using near-infrared technology.
Biocontrol Technology, Inc. has its corporate offices in Pittsburgh, PA
and is involved in the development and manufacture of biomedical devices
and environmental products.
